SCHEMBL15049072

SCHEMBL15049072

CCOC(=O)c1sc(-c2ccc(Cl)cc2)nc1NCCNC

nearest known ligand 0.64

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ TRPM8 Q7Z2W7 6/20 0.64
▸ MAPT P10636 2/20 0.64
▸ CDC7 O00311 5/20 0.58
▸ DBF4 Q9UBU7 5/20 0.58
▸ PTPN11 Q06124 2/20 0.54
▸ GAA P10253 1/20 0.51
▸ SMN1; SMN2 Q16637 3/20 0.50
▸ KMT2A Q03164 2/20 0.50
▸ RAB9A P51151 2/20 0.49
▸ KDM4E B2RXH2 2/20 0.49
▸ NPC1 O15118 1/20 0.49
▸ POLB P06746 1/20 0.49
▸ ALDH1A1 P00352 2/20 0.48
▸ MEN1 O00255 1/20 0.48
▸ LMNA P02545 1/20 0.48
▸ HPGD P15428 1/20 0.48
▸ STAT3 P40763 1/20 0.48
▸ NPSR1 Q6W5P4 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15049166 0.91 TRPM8 (0.62) TRPM8MAPTCDC7DBF4GAA
SCHEMBL15049178 0.89 TRPM8 (0.61) TRPM8MAPTCDC7DBF4PTPN11
SCHEMBL15049292 0.89 TRPM8 (0.64) TRPM8MAPTCDC7DBF4PTPN11
SCHEMBL28245821 0.88 CDC7 (0.57) TRPM8MAPTCDC7DBF4KMT2A
SCHEMBL28246572 0.85 RAB9A (0.61) TRPM8MAPTGAASMN1; SMN2KMT2A
SCHEMBL15049532 0.85 TRPM8 (0.56) TRPM8MAPTCDC7DBF4PTPN11
SCHEMBL2885708 0.82 TRPM8 (0.78) TRPM8MAPTCDC7DBF4PTPN11
SCHEMBL15049127 0.80 TRPM8 (0.62) TRPM8MAPTCDC7DBF4GAA
SCHEMBL28245823 0.79 CDC7 (0.57) TRPM8MAPTCDC7DBF4KMT2A
SCHEMBL15048955 0.78 TRPM8 (1.00) TRPM8MAPTCDC7DBF4PTPN11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2793883-B1 TRPM8 ANTAGONISTS DOMPE FARM SPA (IT) 2018-04-18 — — EP claimed
US-9856246-B2 TRPM8 antagonists DOMPÉ FARMACEUTICI S.P.A. (IT) 2018-01-02 — — US claimed
US-20170129881-A1 TRPM8 ANTAGONISTS DOMPÉ FARMACEUTICI S.P.A. (IT) 2017-05-11 — — US claimed
US-9585875-B2 TRPM8 antagonists DOMPÉ FARMACEUTICI S.P.A. (IT) 2017-03-07 — — US claimed
US-20140371276-A1 TRPM8 ANTAGONISTS DOMPÉ FARMACEUTICI S.P.A. (IT) 2014-12-18 — — US claimed
EP-2793883-A1 TRPM8 ANTAGONISTS Dompe' S.p.A. (IT) 2014-10-29 — — EP claimed
WO-2013092711-A1 TRPM8 ANTAGONISTS DOMPE' S.P.A. (IT) 2013-06-27 — — WO claimed
EP-2606888-A1 Trpm8 antagonists Dompe' S.P.A. (IT) 2013-06-26 — — EP claimed
CN-104220069-B Trpm8 antagonists 多姆皮制药公司 2018-10-02 — — CN disclosed
EP-2793883-B1 TRPM8 ANTAGONISTS DOMPE FARM SPA (IT) 2018-04-18 — — EP disclosed
US-9856246-B2 TRPM8 antagonists DOMPÉ FARMACEUTICI S.P.A. (IT) 2018-01-02 — — US disclosed
US-20170129881-A1 TRPM8 ANTAGONISTS DOMPÉ FARMACEUTICI S.P.A. (IT) 2017-05-11 — — US disclosed
US-9585875-B2 TRPM8 antagonists DOMPÉ FARMACEUTICI S.P.A. (IT) 2017-03-07 — — US disclosed
US-20140371276-A1 TRPM8 ANTAGONISTS DOMPÉ FARMACEUTICI S.P.A. (IT) 2014-12-18 — — US disclosed
EP-2793883-A1 TRPM8 ANTAGONISTS Dompe' S.p.A. (IT) 2014-10-29 — — EP disclosed
WO-2013092711-A1 TRPM8 ANTAGONISTS DOMPE' S.P.A. (IT) 2013-06-27 — — WO disclosed
EP-2606888-A1 Trpm8 antagonists Dompe' S.P.A. (IT) 2013-06-26 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170129881-A1 TRPM8 ANTAGONISTS TRPM8, TRPM7, TRPM5 TRPM8 1/4885MAPT 282/4885CDC7 2527/4885
US-20140371276-A1 TRPM8 ANTAGONISTS TRPM8, TRPM7, TRPV1 TRPM8 1/4885MAPT 293/4885CDC7 3237/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback